相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Increased Activity of a NK-Specific CAR-NK Framework Targeting CD3 and CD5 for T-Cell Leukemias
Elisaveta Voynova et al.
CANCERS (2022)
Knowns and Unknowns about CAR-T Cell Dysfunction
Aleksei Titov et al.
CANCERS (2022)
Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia
Paul M. Maciocia et al.
BLOOD (2022)
Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL
Caroline Diorio et al.
BLOOD (2022)
The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity
Shangkun Zhang et al.
SCIENTIFIC REPORTS (2022)
Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study
Yongxian Hu et al.
CELL RESEARCH (2022)
T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape
Zhenyu Dai et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma
Guru Subramanian Guru Murthy et al.
BLOOD (2021)
Anti-CD21 Chimeric Antigen Receptor (CAR)-T Cells for T Cell Acute Lymphoblastic Leukaemia (T-ALL)
Nicola C. Maciocia et al.
BLOOD (2021)
Anti-CCR9 CAR-T Cells for T Acute Lymphoblastic Leukemia
Paul M. Maciocia et al.
BLOOD (2021)
A Single-Arm, Open-Label, Pilot Trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory TLymphoblastic Leukemia/Lymphoma
Mingzhi Zhang et al.
BLOOD (2021)
CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity
Jiangzhou Shi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Tunable control of CAR T cell activity through tetracycline mediated disruption of protein-protein interaction
Alastair Hotblack et al.
SCIENTIFIC REPORTS (2021)
CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
Pouya Safarzadeh Kozani et al.
STEM CELL RESEARCH & THERAPY (2021)
CRISPR-edited CART with GM-CSF knockout and auto secretion of IL6 and IL1 blockers in patients with hematologic malignancy
Yan Yi et al.
CELL DISCOVERY (2021)
Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
Bijal D. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial
Jing Pan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Rebecca C. Larson et al.
NATURE REVIEWS CANCER (2021)
New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models
Julie A. Hixon et al.
LEUKEMIA (2020)
CAR-NK for tumor immunotherapy: Clinical transformation and future prospects
Wenxiu Wang et al.
CANCER LETTERS (2020)
Durable Remission Following “Off-the-Shelf” Chimeric Antigen Receptor (CAR) T-Cells in Patients with Relapse/Refractory (R/R) B-Cell Malignancies
Kevin J. Curran et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes
Shiwani Agarwal et al.
MOLECULAR THERAPY (2020)
Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
Meir Rozenbaum et al.
FRONTIERS IN IMMUNOLOGY (2020)
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Carlos A. Ramos et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Macrophages enter CAR immunotherapy
Madhura Mukhopadhyay
NATURE METHODS (2020)
CAR-NK cells: A promising cellular immunotherapy for cancer
Guozhu Xie et al.
EBIOMEDICINE (2020)
The evolution of relapse of adult T cell acute lymphoblastic leukemia
Ines Sentis et al.
GENOME BIOLOGY (2020)
CAR-expressing NK cells for cancer therapy: a new hope
Jufeng Xia (Shunichi Arai) et al.
BIOSCIENCE TRENDS (2020)
Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions
Li Zhang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia
Diego Sanchez-Martinez et al.
BLOOD (2019)
A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia
Padma Akkapeddi et al.
LEUKEMIA (2019)
Targeting T Cell Malignancies Using CD4CAR T-Cells and Implementing a Natural Safety Switch
Gina Ma et al.
STEM CELL REVIEWS AND REPORTS (2019)
Anti-CD1a CAR T cells to selectively target T-ALL
Paul M. Maciocia et al.
BLOOD (2019)
Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy
Haitham Khogeer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies
Yingxi Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Unique CDR3 epitope targeting by CAR-T cells is a viable approach for treating T-cell malignancies
Jinqi Huang et al.
LEUKEMIA (2019)
PD-1 Tumor Suppressor Signaling in T Cell Lymphomas
Tim Wartewig et al.
TRENDS IN IMMUNOLOGY (2019)
Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21
SoonHo Kweonl et al.
FRONTIERS IN IMMUNOLOGY (2019)
The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia
Elad Jacoby
BONE MARROW TRANSPLANTATION (2019)
Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix
Wenlong Zhang et al.
BRITISH JOURNAL OF CANCER (2019)
Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells
Justyna Mikula-Pietrasik et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2019)
Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions
Lauren C. Fleischer et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Chimeric antigen receptor T-cell therapies for lymphoma
Jennifer N. Brudno et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies
Maksim Mamonkin et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines
Sunil S. Raikar et al.
ONCOIMMUNOLOGY (2018)
Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia
Jiang Cao et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas
Norbert Schmitz et al.
BLOOD (2018)
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
Miriam Y. Kim et al.
CELL (2018)
Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy
Shivani Srivastava et al.
JOURNAL OF IMMUNOLOGY (2018)
An off-the-shelf fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
Matthew L. Cooper et al.
LEUKEMIA (2018)
Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation
Anna Capsomidis et al.
MOLECULAR THERAPY (2018)
Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy
Lee Ratner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
An Update on Immunotherapy for Solid Tumors: A Review
Toan Pham et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment
Hasan Mollanoori et al.
HUMAN IMMUNOLOGY (2018)
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Marco Ruella et al.
NATURE MEDICINE (2018)
Universal CARs, universal T cells, and universal CAR T cells
Juanjuan Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells
Marion Alcantara et al.
LEUKEMIA (2018)
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
Michael M. Boyiadzis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Simultaneous Targeting of CD19 and CD22: Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study
Persis J. Amrolia et al.
BLOOD (2018)
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas
Irene Scarfo et al.
BLOOD (2018)
TCR alpha beta/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy
Jane Rasaiyaah et al.
JCI INSIGHT (2018)
CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
Xiaojuan Liu et al.
CELL RESEARCH (2017)
Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study
Jonathan Bond et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Robert Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
K. H. Chen et al.
LEUKEMIA (2017)
PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis
Tim Wartewig et al.
NATURE (2017)
Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies
Paul M. Maciocia et al.
NATURE MEDICINE (2017)
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
T. Terwilliger et al.
BLOOD CANCER JOURNAL (2017)
Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
Kevin G. Pinz et al.
ONCOTARGET (2017)
Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies
Yi Tian Png et al.
BLOOD ADVANCES (2017)
RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma
Dennis C. Harrer et al.
BMC CANCER (2017)
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies
Diogo Gomes-Silva et al.
BLOOD (2017)
CD33, not early precursor T-cell phenotype, is associated with adverse outcome in adult T-cell acute lymphoblastic leukaemia
Robert J. Guo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy
Garnet Suck et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells
K. Pinz et al.
LEUKEMIA (2016)
Novel immunotherapies in lymphoid malignancies
Connie Lee Batlevi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
Kevin H. Chen et al.
ONCOTARGET (2016)
The genetics and mechanisms of T cell acute lymphoblastic leukaemia
Laura Belver et al.
NATURE REVIEWS CANCER (2016)
How I treat T-cell acute lymphoblastic leukemia in adults
Mark R. Litzow et al.
BLOOD (2015)
The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy
Mateusz Legut et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2015)
Multifunctional receptor-targeting antibodies for cancer therapy
Yanni Zhu et al.
LANCET ONCOLOGY (2015)
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
S. S. Kenderian et al.
LEUKEMIA (2015)
Acute Lymphoblastic Leukemia in Children
Stephen P. Hunger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Individual Motile CD4+ T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells
Ivan Liadi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
How I treat the peripheral T-cell lymphomas
Alison J. Moskowitz et al.
BLOOD (2014)
The past and future of CD33 as therapeutic target in acute myeloid leukemia
George S. Laszlo et al.
BLOOD REVIEWS (2014)
CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis
Wenli Zheng et al.
LEUKEMIA & LYMPHOMA (2014)
PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
Zhiqiang Guo et al.
PLOS ONE (2014)
Bispecific T-cells Expressing Polyclonal Repertoire of Endogenous γδ T-cell Receptors and Introduced CD19-specific Chimeric Antigen Receptor
Drew C. Deniger et al.
MOLECULAR THERAPY (2013)
Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
David S. Ritchie et al.
MOLECULAR THERAPY (2013)
Novel Therapeutics for Aggressive Non-Hodgkin's Lymphoma
Daruka Mahadevan et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
Michael A. Curran et al.
PLOS ONE (2011)
New drugs for aggressive B-cell and T-cell lymphomas
Niels Murawski et al.
LANCET ONCOLOGY (2010)
Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways
W-L Zhao
LEUKEMIA (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
CD5: A safeguard against autoimmunity and a shield for cancer cells
Ali Dalloul
AUTOIMMUNITY REVIEWS (2009)
Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression
Sabine Mumprecht et al.
BLOOD (2009)
T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)
David I. Marks et al.
BLOOD (2009)
Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia
Xiangli Chen et al.
CANCER BIOLOGY & THERAPY (2008)
The use of intracellular single-chain antibody fragments to specifically inhibit cytokine secretion
KC Daniel et al.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2001)
分享论文
